Related Experiment Video
Updated: Jul 28, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor
Toni L Cordero1, Zheng Dai1, Arcelia Arrieta2
1Medtronic, Northridge, California, USA.
Diabetes Technology & Therapeutics
|May 30, 2023
Summary
The MiniMed™ 780G system with Guardian™ 4 Sensor demonstrated safe and effective glucose control in adolescents and adults. This advanced hybrid closed-loop system improved glycemic metrics, showing promise for diabetes management.
Area of Science:
- Endocrinology
- Biomedical Engineering
- Diabetes Technology
Background:
- Previous studies showed benefits of the MiniMed™ advanced hybrid closed-loop (AHCL) system with Guardian™ Sensor 3.
- The MiniMed™ 780G system with Guardian™ 4 Sensor (MM780G+G4S) offers calibration-free continuous glucose monitoring (CGM).
Purpose of the Study:
- To evaluate early outcomes of the MM780G+G4S in participants transitioning from a previous system.
- To compare these outcomes with real-world data from a large user population.
Main Methods:
- Descriptive analysis of glycemic metrics, insulin delivery, and system usage in continued access study (CAS) participants and real-world users.
- Data collected from 109 pediatric and 67 adult CAS participants, and over 36,000 real-world users.
- Minimum 10 days of CGM data required for analysis.
Main Results:
- High time in advanced hybrid closed-loop (AHCL) and CGM use (>90%) with minimal system exits and blood glucose measurements.
- Adults in both cohorts met most glycemic target recommendations.
- Pediatric groups achieved targets for time in range (TIR) and time below range (TBR), with potential for improvement in glucose variability and time above range (TAR) through optimized settings.
Conclusions:
- The MM780G+G4S system is safe for early clinical use with minimal user interventions.
- Outcomes align with real-world data, demonstrating achievement of recommended glycemic targets.
- The system shows significant potential for improving diabetes management in both pediatric and adult populations.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
217
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
217
01:06Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
01:22Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
01:15Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306
01:15Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
241
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241